16:46:06 EDT Wed 24 Jun 2026
Enter Symbol
or Name
USA
CA



The Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today

2026-06-24 08:45 ET - News Release

Believes New Independent Directors Are Needed to Correct the Board’s Misaligned Priorities and Prevent Further Value Destruction

Reveals Seer’s Board Has Not Responded to the Radoff-JEC Group’s Stockholder-Friendly Offer Made on June 15 to Resolve the Ongoing Proxy Contest, Demonstrating the Board's Focus on its Own Entrenchment


HOUSTON -- (Business Wire)

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624630276/en/

Source: FactSet, Company proxy statements. Graph and figures are from December 4, 2020 through December 31, 2025.

Source: FactSet, Company proxy statements. Graph and figures are from December 4, 2020 through December 31, 2025.

  • Seer’s Board of Directors (the “Board”) has destroyed value for stockholders while enriching Company insiders:
    • The Company has posted a -97.0% share price decline since its December 2020 IPO.1
    • Seer has generated cumulative reported losses exceeding $465 million since its IPO.2
    • Seer has delivered virtually no revenue growth over the last three fiscal years, while investing over $160 million.3
    • The Board has rewarded Chairman and CEO Omid Farokhzad, M.D. with nearly $37 million in cumulative compensation while a stockholder who purchased one share at the time of the IPO ($19.00) would be left with less than $0.63.4
  • Seer has no plan to create stockholder value under Chairman and CEO Omid Farokhzad, M.D.:
    • Dr. Farokhzad has destroyed more than $1 billion in investor capital across five separate companies, evidence supporting our belief that he is incapable of turning around Seer.5
    • The strategic plan overseen by the Board anticipates Seer will not achieve profitability until 2031.6
    • The Board rejected our three proposals to acquire Seer for premiums of 33% - 42% to its unaffected share price and a contingent value right – proposals which we believe provide substantially greater certainty of value creation than the Company’s current strategic plan – without even engaging with us.
  • Seer’s Board has not responded to our proposal to settle this proxy contest:
    • On June 15, 2026, we proposed to end our ongoing proxy contest in exchange for Seer adopting governance enhancements and conducting a tender offer for 20 million shares at $2.50 per share, which would be in line with the Board’s authorized buyback program and management’s statements that there is a “significant dislocation” in the Company’s share price.7
    • More than a week later, the Board has still not responded to our settlement offer – which it requested in the first place – demonstrating that its priority is not delivering value or governance improvements for stockholders.
    • Instead of focusing on opportunities to maximize value for stockholders as Seer’s share price has consistently traded at a significant discount to net cash, the Board has diluted stockholders by repeatedly issuing large grants of restricted stock units and in-the-money options to Dr. Farokhzad and President and CFO David Horn.

Vote FOR the Radoff-JEC Group’s Nominees – Howard H. Berman, Ph.D., Joshua S. Horowitz and Luis E. Rinaldini – Today to Prevent Further Value Destruction

Do NOT Vote for Omid Farokhzad, M.D., Terrance McGuire or Dipchand (Deep) Nishar

Questions about how to vote? Contact (888) 368-0379 or info@saratogaproxy.com.

Visit www.SaratogaProxy.com/SEER to learn more.

_________________________________________

1FactSet. Share price decline from December 4, 2020 through April 10, 2026, the trading day immediately prior to the Radoff-JEC Group’s submission of its initial proposal to acquire the Company.

2 The Company’s Form 10-K for the year ended December 31, 2025 filed on March 2, 2026.

3 Company Form 10-K filings.

4 Company proxy statements. FactSet; share price decline from December 4, 2020 through December 31, 2025.

5 Seer, BIND Therapeutics, Inc., Selecta Biosciences, Inc., Tarveda Therapeutics, Inc. and Senti Biosciences Holdings, Inc.

6 Company PRE 14A filed on October 10, 2025.

7 On the Company’s Q1 2026 earnings call held on May 13, 2026, President and CFO David Horn said: “Our opportunistic share repurchase in the quarter reflect our continued belief that there is a significant dislocation in our share price.”

 

Contacts:

Greg Lempel
greg@fondrenlp.com

or

Saratoga Proxy Consulting LLC
John Ferguson / Joseph Mills, 212-257-1311
info@saratogaproxy.com

Source: On Behalf of The Radoff-JEC Group

© 2026 Canjex Publishing Ltd. All rights reserved.